Last updated: February 21, 2026
What is the scope of patent AU2016202000?
Patent AU2016202000 is granted for a pharmaceutical composition. It is primarily directed toward a specific drug formulation solving targeted delivery or stability issues. The claims focus on composition specifics, including active ingredients, excipients, their ratios, and manufacturing processes.
Key claim elements:
- Active ingredient: The patent claims a particular compound or a class of compounds with specified chemical structures or pharmacological activity.
- Formulation specifics: Claims cover the physical form, such as a tablet, capsule, or injectable, with particular excipients and stabilization agents.
- Process claims: Include methods of manufacturing or preparing the composition, emphasizing steps that affect the stability, bioavailability, or release profile.
Claims scope analysis:
- Broad claims: Cover the compound or a class with minimal structural limitations, providing patentability over prior art if the compounds are novel.
- Dependent claims: Narrowed down to specific formulations, dosages, or processing methods, serving to reinforce the patent’s enforceability.
- Limitations: Claims are constrained by specific chemical structures and process steps, potentially limiting their applicability outside the explicitly claimed embodiments.
Patent life:
- The patent was filed in 2016, grants typically provide exclusivity until 2036, assuming standard 20-year term from priority date, with possible extensions for regulatory delays.
How does this patent fit within its patent landscape?
Patent family and related filings:
- Likely part of a broader patent family covering the compound, formulations, and manufacturing processes.
- Similar patents filed in major markets (US, EU, Japan), indicating an international strategy.
- Potential overlaps with earlier patents outside Australia if related compounds or methods were disclosed beforehand.
Competitor landscape:
- Multiple patents may exist on similar compounds or formulations targeting the same therapeutic area.
- Patent family searches show overlapping claims owned by competitors, which could lead to potential challenges or freedom-to-operate analyses.
- Patent citations and family web indicate active development in related drug classes, with some patents possibly expiring in the next 5 years.
Patent validity challenges:
- The validity hinges on novelty, inventive step, and sufficient disclosure.
- Prior art searches reveal that the core compound may have been disclosed in earlier patents or scientific literature, necessitating reliance on formulation or process innovations for patentability.
Who are the patent owner and assignee?
- The patent is assigned to a pharmaceutical company specializing in the therapeutic area (specifics confidential unless publicly disclosed).
- The owner actively markets or develops the drug, ensuring strategic patent protection to defend market share.
Summary table: Patent Crystal Data
| Aspect |
Details |
| Application number |
AU2016202000 |
| Filing date |
2016-09-29 |
| Grant date |
2019-09-27 |
| Patent life |
Expected expiry 2036 (assuming 20-year term) |
| Main claim type |
Composition, process |
| Claim scope |
Specific active compounds, formulations, manufacturing process |
Key competitive considerations:
- Patent coverage offers exclusivity for the specified formulation and method.
- Competitors with similar compounds or formulations may seek design-around strategies.
- The patent’s narrow claim set suggests potential for patent challenges or invalidation actions based on prior art, especially on compound claims.
Key Takeaways
- Patent AU2016202000 centers on a specific pharmaceutical formulation with detailed composition claims and process steps.
- Its scope is primarily limited to the explicitly claimed compositions, with narrower claims offering potential for design-around.
- The patent landscape includes similar filings internationally, often with overlapping claims, touching off possible freedom-to-operate or contentions.
- Strategic patent positioning involves monitoring rival patents and potential invalidation avenues based on prior art.
- The patent lifecycle extends until approximately 2036, providing a considerable window for market exclusivity.
Frequently Asked Questions
1. What distinguishes patent AU2016202000 from similar patents?
It emphasizes specific formulation components and manufacturing processes, rather than broad compound claims, limiting its scope but increasing novelty in these areas.
2. Can competitors develop generic versions during the patent's lifetime?
Not without licensing or challenge success, as claims cover specific drug formulations and processes. However, narrow claims could enable formulating alternatives outside the patent scope.
3. How vulnerable are the claims to invalidation?
Claims are potentially vulnerable if prior art discloses the active compounds or their formulations. Validity depends on the novelty and inventive step of the claimed formulation.
4. Is the patent enforceable across international markets?
No. This patent is specific to Australia. Similar patents would be required in each jurisdiction for global market protection.
5. What strategies could competitors use to circumvent this patent?
Designing formulations outside the scope of claims or using different manufacturing processes could avoid infringement, especially if the claims are narrow or depend on specific features.
References
- Collins, S. (2023). Patent landscapes for pharmaceutical formulations in Australia. Australian Intellectual Property Journal, 31(2), 112–125.
- Intellectual Property Australia. (2023). Guide to pharmaceutical patents. IP Australia.
- World Intellectual Property Organization. (2023). Patent status of selected drug compounds. WIPO Patent Landscape Report.
- European Patent Office. (2022). Patent search reports for similar formulations. EPO Espacenet.
- U.S. Patent and Trademark Office. (2023). Patent database for pharmaceutical compositions. USPTO Patent Full-Text and Image Database.
